News & Updates

Show Multimedia Only

Risk factors for late-onset epilepsy among people with cognitive decline identified

16 Jun 2025

Factors such as APOE4 allele, dementia onset before age 60 years, Alzheimer’s disease (AD) dementia subtype, worse cognition, stroke/transient ischaemic attack (TIA), and Parkinson’s disease (PD) all contribute to a heightened risk of late-onset epilepsy in people with cognitive decline, as reported in a study.

Risk factors for late-onset epilepsy among people with cognitive decline identified

16 Jun 2025

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025 by

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025

Vitamin D protective against BPPV

16 Jun 2025 by

A group of researchers from Changi General Hospital in Singapore found lower rates of benign paroxysmal positional vertigo (BPPV) recurrence among older adults who supplemented their diet and Canalith Repositioning Procedure (CRP) with vitamin D.

Vitamin D protective against BPPV

16 Jun 2025

VTE event risk up in PD patients

12 Jun 2025 by

Researchers from Singapore found an elevated risk of venous thromboembolism (VTE) events in individuals with Parkinson’s disease (PD) in a systematic review and meta-analysis of 13 studies.

VTE event risk up in PD patients

12 Jun 2025

Fewer migraine days with zonisamide in children

11 Jun 2025 by

A retrospective cohort study presented at AAN 2025 has demonstrated that prophylactic zonisamide can significantly reduce headache days per month (HDPM) in paediatric patients with migraine.

Fewer migraine days with zonisamide in children

11 Jun 2025

Innovative biodegradable biohybrid targeted therapy for intracranial tumours

11 Jun 2025 by

The world’s first magnetically driven nonimmunogenic blood hydrogel fibre robot for treatment of deep-seated brain tumours have been successfully developed by a collaborative research team from the Chinese University of Hong Kong (CUHK), the Shenzhen University and the Shenzhen Institutes of Advanced Technology (SIAT).

Innovative biodegradable biohybrid targeted therapy for intracranial tumours

11 Jun 2025

TRICH score predicts triple antihypertensive therapy need after ICH

10 Jun 2025 by

A team from the LKS Faculty of Medicine at the University of Hong Kong (HKU) has developed an innovative clinical tool to help physicians effectively identify intracerebral haemorrhage (ICH) patients who would benefit from early initiation of triple antihypertensive therapy to reduce the risks of ICH recurrence and subsequent strokes.

TRICH score predicts triple antihypertensive therapy need after ICH

10 Jun 2025

A new era in Alzheimer's disease management – are we ready?

09 Jun 2025 by

The availability of new diagnostics and new amyloid-targeting therapies as well as the shift in approach from symptom management to targeting disease pathology mark a truly new era in Alzheimer’s disease (AD) management, according to Professor Jeffrey Burns of the Alzheimer's Disease Research Centre, The University of Kansas, Kansas, US, who spoke at the 29^th Hong Kong Medical Forum.

A new era in Alzheimer's disease management – are we ready?

09 Jun 2025

Autism spectrum disorder tied to heightened risk of Parkinson’s disease

09 Jun 2025

Individuals with autism spectrum disorder face an increased risk of Parkinson’s disease (PD), independent of depression or antidepressant use and antipsychotic exposure, according to a nationwide population-based prospective cohort study.

Autism spectrum disorder tied to heightened risk of Parkinson’s disease

09 Jun 2025

Prenatal triptan exposure unlikely to harm neurodevelopmental outcomes in children

08 Jun 2025 by

Maternal use of the migraine drug triptans before or during pregnancy does not appear to put infants at risk of developing neurodevelopmental disorders, according to a study.

Prenatal triptan exposure unlikely to harm neurodevelopmental outcomes in children

08 Jun 2025

News & Updates

Showing Neurology articles

Showing

Specialty:

Risk factors for late-onset epilepsy among people with cognitive decline identified

Risk factors for late-onset epilepsy among people with cognitive decline identified

Fremanezumab tackles migraine, depression at the same time

Fremanezumab tackles migraine, depression at the same time

Vitamin D protective against BPPV

Vitamin D protective against BPPV

VTE event risk up in PD patients

VTE event risk up in PD patients

Fewer migraine days with zonisamide in children

Fewer migraine days with zonisamide in children

Innovative biodegradable biohybrid targeted therapy for intracranial tumours

Innovative biodegradable biohybrid targeted therapy for intracranial tumours

TRICH score predicts triple antihypertensive therapy need after ICH

TRICH score predicts triple antihypertensive therapy need after ICH

A new era in Alzheimer's disease management – are we ready?

A new era in Alzheimer's disease management – are we ready?

Autism spectrum disorder tied to heightened risk of Parkinson’s disease

Autism spectrum disorder tied to heightened risk of Parkinson’s disease

Prenatal triptan exposure unlikely to harm neurodevelopmental outcomes in children

Prenatal triptan exposure unlikely to harm neurodevelopmental outcomes in children